NuCana plc (NCNA)
| Previous close | 0.5990 |
| Open | 0.6300 |
| Bid | 0.5900 x 900 |
| Ask | 0.6100 x 1300 |
| Day's range | 0.5990 - 0.6300 |
| 52-week range | 0.5600 - 1.7500 |
| Volume | |
| Avg. volume | 44,700 |
| Market cap | 31.966M |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.7200 |
| Earnings date | 14 Nov 2023 - 20 Nov 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
ZacksBears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now
NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
- Globe Newswire
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 being held October 11-15, 2023 in Boston, Massachusetts. The details of NuCana’s presentations at the meeting are as follows: Abstract title: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with adva
Simply Wall St.Here's Why We're Watching NuCana's (NASDAQ:NCNA) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although...
